Compare AUTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUTL | PCRX |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 1.1B |
| IPO Year | 2025 | 2010 |
| Metric | AUTL | PCRX |
|---|---|---|
| Price | $2.10 | $25.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.50 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 2.6M | 415.8K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | $10,120,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $80.32 | $6.78 |
| Revenue Next Year | $53.96 | $8.54 |
| P/E Ratio | ★ N/A | $136.16 |
| Revenue Growth | ★ 496.00 | 26.04 |
| 52 Week Low | $1.18 | $18.80 |
| 52 Week High | $2.58 | $27.66 |
| Indicator | AUTL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 50.12 |
| Support Level | $1.37 | $24.61 |
| Resistance Level | $2.43 | $26.94 |
| Average True Range (ATR) | 0.10 | 0.61 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 3.23 | 56.00 |
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.